Adjuvant therapy for cutaneous malignant melanoma

被引：23

作者：

Demierre, MF

Koh, HK

机构：

[1] BOSTON UNIV,SCH MED,MED CTR,DEPT DERMATOL,BOSTON,MA 02118

[2] BOSTON UNIV,SCH MED,DEPT MED,BOSTON,MA 02118

[3] BOSTON UNIV,SCH MED,DEPT EPIDEMIOL,BOSTON,MA 02118

[4] BOSTON UNIV,SCH MED,DEPT BIOSTAT,BOSTON,MA 02118

[5] BOSTON UNIV,SCH PUBL HLTH,DEPT BIOSTAT,BOSTON,MA 02118

[6] BOSTON UNIV,SCH PUBL HLTH,DEPT EPIDEMIOL,BOSTON,MA 02118

[7] BOSTON UNIV,SCH PUBL HLTH,DEPT MED,BOSTON,MA 02118

[8] BOSTON UNIV,SCH PUBL HLTH,DEPT DERMATOL,BOSTON,MA 02118

[9] BOSTON MED CTR,SKIN ONCOL PROGRAM,BOSTON,MA

来源：

JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY | 1997年 / 36卷 / 05期

基金：

美国国家卫生研究院;

关键词：

D O I：

10.1016/S0190-9622(97)80329-5

中图分类号：

R75 [皮肤病学与性病学];

学科分类号：

100206 ;

摘要：

We discuss the current status of adjuvant therapy for melanoma by first reviewing the rationale and goals of adjuvant therapy and then analyzing the results of published randomized trials. We pay particular attention to adjuvant interferon trials that raise many challenging issues in the management of patients with melanoma at high risk of recurrence. Past adjuvant trials have used immunotherapeutic approaches, chemotherapy, radiation therapy, as well as hormonal and retinoid therapy. We also summarize ongoing adjuvant trials.

引用

页码：747 / 764

页数：18

共 171 条

[1] IMPROVED GRAPHS FOR CALCULATING SAMPLE SIZES WHEN COMPARING 2 INDEPENDENT BINOMIAL DISTRIBUTIONS [J].